7.4. MEDICATION Medications taken in the 28 days before Day 1, will be recorded. Medications will be coded using the World Health Organization Drug Dictionary (WHODRUG) version Q1 March 2014. 7.5. PRIOR AND CONCOMITANT MEDICATIONS Prior medications include medications started prior to the first dose date of study m edication. Concomitant medications include medications started on or after Day 1. Medicati ons that started before the first dose of study drug and continued afterwards will be identified as both prior and concomitant medications. For prior and concomitant medications with incomplete dates, the following ru les will be used to impute start and/or stop dates for the purposes of determining if a medication is prior or concomitant only.  For start dates, if day is missing the first of the month will be used. If m onth and day are missing January 01 will be used. If the start date is completely missing, t he date of first dose will be used. If the stop date is complete and the imputed start date is aft er the actual stop date, then the start date will be imputed as the stop date.  For stop dates, if the day is missing then the last day of the month will be used. If the month and day are missing then December 31 will be used. If the stop date is completely missi ng then the date of last dose will be used. If the start date is complete and the impute d stop date is earlier than the actual start date, the stop date will be imputed as the start date. Both prior and concomitant medications will be summarized. Concomitant corticosteroid and anti- convulsant medications will be summarized separately from other concomitant medicati ons. For the summary tables, the count and percentage of subjects under each anatomical therapeutic chemical (ATC) class level 2 and preferred name will be summarized by treat ment group. If a DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Stemline Therapeutics, Inc. Protocol: STML- 701-0114 Version 3.0, 10-JUL-2015 (Amendment 2) Statistical Analysis Plan Page 29 of 63 subject has taken 1 or more prior or concomitant medications more than once, the subject wi ll be counted only once under any given drug class. A listing of prior and concomitant medications will be provided for all tr eated subjects. A flag will be included in the listing to indicate whether a medication is prior, concomitant, or both prior and concomitant. 7.5.1. Prohibited Medications and Restrictions Therapies including agents administered primarily for anti-tumor intent, in cluding chemotherapy, bevacizumab (in Stage 1; or other VEGF/VEGF receptor [VEGFR]-directedagent), or investigational anticancer agents are prohibited during participation in the study. Use of prohibited medications will be summarized by ATC class (Level 2) and PT. DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Stemline Therapeutics, Inc. Protocol: STML- 701-0114 Version 3.0, 10-JUL-2015 (Amendment 2) Statistical Analysis Plan Page 30 of 63 8.